Previous Close | 1.95 |
1-Year Change | 427.03% |
6-Months Change | 204.69% |
3-Months Change | 126.74% |
Moving Avg (50d) | 1.3905 |
Moving Avg (200d) | 0.8563 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 345.5M |
Beta (3-Years) | 1.68 |
Revenue Growth (ttm) | 79.75% |
Net Profit Margin (ttm) | -123.89% |
Return On Assets (ttm) | -113.58% |
EPS (ttm) | -1.45 |
PE Ratio (ttm) | -1.34 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases. Wikipedia